Q32 Bio
Claire Galand began their career in 2006 as a Summer Student in the Kaveri lab at the Centre de Recherche des Cordeliers. In 2008, they began their PhD in Immunology at the same institution, working with Pr Catherine Fridman and Pr Sylvain Fisson in the team #13 "Immune micro-environment and tumors". In 2010, they became a Flow Cytometry Laboratory Teaching Assistant at the Pierre and Marie Curie University (Paris 6). In 2012, they moved to the Boston Children's Hospital, where they worked as a Postdoctoral Research Fellow in Immunology in the Geha lab. In 2017, they joined Agenus as an Associate Director, Head of Preclinical Biomarker Discovery, and then Senior Scientist and Scientist II, where they were the Biology lead for monospecific antibodies targeting immune check point modulators. In 2022, they moved to Q32Bio Inc. as the Director Translational Biology.
Claire Galand received their Bachelor degree in Biology from Université de Rennes I in 2006. Claire then went on to pursue their Master's degree in Immunology from Pierre and Marie Curie University in 2007, and completed their PhD in Immunology from the same university in 2011.
This person is not in any offices
Q32 Bio
1 followers
Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases.